High Court Quashes Prosecution: Retrospective Application of Drug Standards Deemed Unlawful

A High Court has quashed the prosecution of a drug manufacturer, ruling that the retrospective application of drug standards is unlawful. The case involved Mediplus Scalp Vein Set, manufactured in 2004 before Maharashtra implemented new standards in 2005. The court found that prosecuting the manufacturer for not adhering to standards set after the product's manufacture was an abuse of process.

Case Overview

The case centers around a complaint filed against the manufacturer (Petitioner No. 3) of Mediplus Scalp Vein Set, based on a sample found non-compliant with Indian Pharmacopoeia (IP) requirements for sterility. The sample, from a Nanded hospital's drug store, was collected in June 2005, analyzed in September 2005, and resulted in a complaint filed in January 2006. The Chief Judicial Magistrate, Nanded, issued process against the manufacturer. However, the manufacturer only learned of the case in April 2022 and subsequently petitioned the High Court.

Arguments Presented

The manufacturer argued that no standards existed for their product when it was manufactured in October 2004. The Maharashtra State only introduced these standards in October 2005. Therefore, they contended, prosecuting them for non-compliance was a retrospective application of the law, violating fundamental principles of justice. They further argued that the Magistrate's order lacked sufficient application of mind.

The State argued that the drug was sold after the standard was implemented, constituting a continuing offense. They also highlighted the manufacturer's failure to respond to a notice to withdraw the product from the market.

Legal Precedents and Reasoning

The High Court considered the maintainability of the writ petition, citing precedents which established that such petitions are maintainable even without first challenging the order before the lower court. The court then analyzed whether the Magistrate's order demonstrated sufficient application of mind, finding it lacking.

The pivotal aspect of the judgment centered on the retrospective application of the standard:

"This Court, therefore finds that prosecuting manufacturer would be clearly an abuse of process of law as a person cannot be held guilty for the act done prior to notification prescribing standard."

The court emphasized that Section 18(a)(i) of the Drugs and Cosmetics Act, 1940, prohibits the manufacture of non-standard drugs only from the date the State Government notifies the standard. Since the standard was introduced after the product's manufacture, the prosecution was deemed unlawful.

Court Decision and Implications

The High Court allowed the writ petition, quashing the order for issuance of process. This decision highlights the importance of the principle against retrospective application of laws, particularly in cases involving criminal prosecution. It underscores that individuals should only be held accountable for actions violating laws in effect at the time of the action. The judgment serves as a critical reminder for legal authorities to ensure careful consideration of the temporal aspects of legislation when initiating criminal proceedings.